Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

Chronic obstructive pulmonary disease (COPD) and heart failure (CHF) are common
conditions. The prevalence of COPD ranges from 20% to 30% in patients with CHF. The …

Background β-Adrenergic agonists exert physiologic effects that are the opposite of those of
β-blockers. β-Blockers are known to reduce morbidity and mortality in patients with cardiac …

Das vorliegende Dokument ist eine Neufassung und Aktualisierung der Leitlinie zur
Diagnostik und Therapie von Patienten mit COPD, die die bisherige Version aus dem Jahr …

Aims: To quantify the prevalence of heart failure and left ventricular systolic dysfunction
(LVSD) in chronic obstructive pulmonary disease (COPD) patients and vice versa. Further, to …

Short-acting β-adrenergic receptor agonists have pharmacologically predictable dose-
related and potency-related adverse effects, including tachycardia and tremor, and they also …

Bronchodilators form the foundation of symptomatic treatment of COPD. Several long-acting
bronchodilators are now available for use in COPD, but publications of large-scale studies of …

Der folgende Text stellt eine Überarbeitung der Leitlinie der Deutschen Atemwegsliga und
der Deutschen Gesellschaft für Pneumologie von 2002 [1] dar. Diese ist notwendig …

Chronic obstructive pulmonary disease (COPD) is independently associated with atrial
fibrillation (AF). Decreased oxygenation, hypercapnia, pulmonary hypertension, diastolic …

Despite the passionate debate over the use of β2‐adrenoceptor agonists in the treatment of
airway disorders, these agents are still central in the symptomatic management of asthma …